CTOs on the Move

GTC Biotherapeutics, Inc.

www.gtc-bio.com

 
GTC Biotherapeutics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gtc-bio.com
  • 175 Crossing Blvd Ste 410
    Framingham, MA USA '01702
  • Phone: 508.620.9700

Executives

Name Title Contact Details

Similar Companies

automation X

automation X is a Vienna, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bloodworth Wholesale

Bloodworth Wholesale is a Tifton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Amring Pharmaceuticals

Amring promotes health across communities by providing reliable, safe, and affordable medications bringing value to patients and improving quality of life.

Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.